Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 4/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 5/20 | 0.46 |
| ▸ | TGM2 | P21980 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9472806 | 0.86 | CES1 (0.67) | CA1CA2CES1LRRK2MAP3K7 | |
| SCHEMBL9472812 | 0.86 | CES1 (0.67) | CA1CA2CES1LRRK2MAP3K7 | |
| SCHEMBL12804862 | 0.82 | LRRK2 (0.67) | CA1CA2CES1LRRK2MAP3K7 | |
| SCHEMBL12805002 | 0.82 | CES1 (0.62) | CA1CA2CES1LRRK2MAP3K7 | |
| SCHEMBL12804858 | 0.82 | LRRK2 (0.67) | CA1CA2CES1LRRK2MAP3K7 | |
| SCHEMBL12805007 | 0.82 | CES1 (0.62) | CA1CA2CES1LRRK2MAP3K7 | |
| SCHEMBL5988490 | 0.81 | ALDH1A1 (0.64) | CA1CA2LRRK2RETTGM2 | |
| SCHEMBL457929 | 0.80 | CES1 (1.00) | CA1CA2CES1LRRK2RET | |
| SCHEMBL29475283 | 0.80 | CES1 (1.00) | CA1CA2CES1LRRK2RET | |
| SCHEMBL14446594 | 0.78 | CES1 (0.72) | CA1CA2CES1LRRK2MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CA1 2666/4885CA2 1116/4885CES1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.